decad
prior
human
outbreak
emerg
zoonot
virus
caus
fatal
hemorrhag
fever
ebola
viru
ebov
enceph
nipah
viru
niv
rel
sporad
small
term
case
number
rang
isol
singl
case
sever
hundr
case
cdc
lubi
gurley
histor
largest
ebov
outbreak
highlight
rel
pauciti
efficaci
therapeut
vaccin
avail
deploy
pathogen
despit
extens
preclin
studi
demonstr
efficaci
therapeut
antibodi
vaccin
biosafeti
pathogen
broder
et
al
geisbert
et
al
mendoza
et
al
mire
et
al
qiu
et
al
identifi
therapeut
could
repurpos
ebov
vitro
screen
librari
fdaapprov
compound
conduct
screen
among
other
antivir
nucleosid
nucleotid
analog
madrid
et
al
veljkov
et
al
welch
et
al
last
year
develop
antivir
nucleosid
nucleotid
analog
primarili
direct
toward
combat
virus
respons
chronic
infect
human
immunodefici
viru
herp
virus
hepat
virus
ray
hitchcock
klumpp
colleagu
first
demonstr
vitro
activ
c
hepat
c
viru
hcv
singlestrand
positivesens
rna
viru
klumpp
et
al
develop
prodrug
balapiravir
halt
follow
find
toxic
low
efficaci
compound
clinic
trial
treat
hcv
dengu
viru
nelson
et
al
nguyen
et
al
despit
vitro
activ
divers
flavivirus
public
health
import
dengu
viru
tickborn
enceph
viru
suggest
may
templat
develop
modifi
analog
antivir
activ
eyer
et
al
interestingli
analog
recent
shown
also
inhibit
respiratori
syncyti
viru
rsv
singlestrand
negativesens
rna
viru
clark
et
al
deval
et
al
wang
et
al
follow
studi
describ
potent
antivir
activ
repres
member
paramyxovirida
famili
includ
henipavirus
niv
hendra
viru
hev
given
vitro
antivir
properti
analog
c
c
respect
rsv
highli
conserv
nucleotid
bind
domain
share
across
pneumovirida
paramyxovirida
filovirida
famili
evalu
compar
antivir
potenc
cytidin
analog
repres
paramyxovirus
filovirus
includ
makona
variant
ebov
albarino
et
al
studi
document
suscept
paramyxovirus
filovirus
analog
reinforc
prospect
develop
nucleosid
analog
potenti
broadspectrum
therapeut
rna
virus
public
health
import
work
infecti
viru
perform
class
biosafeti
cabinet
work
util
live
nipah
viru
niv
hendra
viru
hev
ebola
viru
ebov
sudan
viru
sudv
ravn
viru
ravv
marburg
viru
marv
rift
valley
fever
viru
rvfv
conduct
laboratori
center
diseas
control
prevent
cdc
atlanta
ga
hela
sknmc
cell
purchas
american
type
tissu
cultur
collect
atcc
manassa
va
usa
hela
sknmc
cell
propag
dulbecco
modifi
eagl
medium
dmem
life
technolog
carlsbad
ca
usa
supplement
volvol
fetal
calf
serum
fc
hyclon
thermo
scientif
waltham
usa
penicillinstreptomycin
life
technolog
cell
propag
roswel
park
memori
institut
medium
rpmi
supplement
fc
cell
obtain
apath
llc
brooklyn
ny
usa
propag
dmem
supplement
fc
nonessenti
amino
acid
life
technolog
normal
human
small
airway
epitheli
cell
saec
purchas
atcc
propag
airway
epitheli
cell
basal
medium
supplement
bronchial
epitheli
cell
growth
kit
atcc
niv
malaysian
genotyp
recombin
niv
malaysian
genotyp
express
fluoresc
protein
lo
et
al
hev
recombin
measl
viru
mv
edmonstonzagreb
strain
express
enhanc
green
fluoresc
protein
rmv
ez
egfp
rennick
et
al
ebov
makona
variant
recombin
ebov
mayinga
variant
repres
ebolaviru
genu
sudv
gulu
variant
sanchez
rollin
ravv
ravn
variant
johnson
et
al
recombin
rvfv
express
enhanc
green
fluoresc
protein
rvfvgfp
bird
et
al
propag
either
vero
atcc
vero
atcc
cell
quantit
tissu
cultur
infect
dose
tcid
assay
use
reed
muench
method
reed
muench
recombin
ebov
makona
variant
express
ebovzsg
albarino
et
al
recombin
marv
variant
express
marvzsg
propag
quantit
use
cell
recombin
respiratori
syncyti
viru
rsv
express
enhanc
green
fluoresc
protein
hallak
et
al
propag
quantit
use
hela
cell
recombin
human
parainfluenza
viru
express
enhanc
green
fluoresc
protein
js
strain
zhang
et
al
obtain
viratre
propag
quantit
use
vero
cell
c
c
fig
correspond
triphosph
synthes
alio
biopharma
recombin
rsv
lp
produc
coexpress
rsv
l
p
protein
baculoviru
express
system
accord
previous
describ
procedur
noton
et
al
reaction
mixtur
compos
modifi
templat
sequenc
ugcg
cuuguuu
recombin
rsv
lp
polymeras
primer
buffer
mm
tri
ph
mm
kcl
mm
mm
dtt
triton
dmso
p
gtp
final
volum
reaction
start
addit
ntp
incub
min
quench
addit
gel
load
buffer
ambion
sampl
run
h
w
polyacrylamid
urea
sequenc
gel
gel
expos
phosphorscreen
scan
triphosph
tp
format
measur
hela
sknmc
cell
ctp
ctp
format
measur
hela
cell
maintain
cultur
alio
biopharma
cell
seed
sixwel
plate
cellswel
correspond
media
incub
overnight
cell
cultur
incub
co
use
experi
c
c
ad
well
incub
h
co
end
incub
medium
remov
cell
wash
twice
cold
sodium
chlorid
water
cell
lyse
methanolwat
vv
extract
supernat
dri
reconstitut
mm
ammonium
phosphat
lcmsm
analysi
determin
correspond
ctp
ctp
level
chen
et
al
concentr
ctp
ctp
normal
number
cell
report
picomol
per
million
cell
virus
express
fluoresc
gfp
zsgreen
protein
assay
fluoresc
use
synergi
plate
reader
biotek
cell
saec
seed
cell
per
well
black
opaqu
plate
corn
corn
ny
perkinelm
cellcarri
ultra
plate
waltham
compound
ad
assay
plate
h
assay
plate
transfer
suit
appropri
infect
tcid
per
cell
respect
viru
read
h
postinfect
hpi
depend
viru
use
fluoresc
signal
dmsotreat
infect
cell
set
gfp
effect
concentr
ec
calcul
use
fourparamet
variabl
slope
nonlinear
regress
fit
mean
valu
assay
perform
quadrupl
graphpad
prism
la
jolla
ca
cell
saec
seed
cell
per
well
white
opaqu
plate
compound
ad
assay
plate
assay
plate
transfer
suit
infect
tcid
per
cell
analyz
celltiterglo
promega
madison
wi
h
postinfect
pi
synergi
plate
reader
valu
normal
uninfect
cell
control
accord
viabil
follow
viabil
specif
valuerefer
valu
dmso
control
valuerefer
valu
refer
valu
deriv
control
well
without
cell
uninfect
cell
control
valu
subtract
refer
valu
set
inhibit
cpe
ec
valu
calcul
use
fourparamet
variabl
slope
nonlinear
regress
fit
valu
celltiterglo
assay
also
use
determin
viabil
uninfect
cell
treat
serial
dilut
compound
h
day
h
day
valu
normal
dmso
control
accord
viabil
follow
viabil
specif
valuerefer
valu
dmso
control
valuerefer
valu
refer
valu
deriv
control
well
without
cell
dmso
control
valu
subtract
refer
valu
set
viabil
viabilitycytotox
cc
valu
calcul
use
fourparamet
variabl
slope
nonlinear
regress
fit
mean
valu
deriv
quadrupl
sampl
measur
compound
inhibit
filoviru
infect
spread
cell
saec
treat
compound
infect
tcid
ebov
sudv
ravv
marvzsg
day
pi
cell
fix
formalin
supplement
tritonx
deterg
stain
primari
rabbit
antiebov
polyclon
serum
sever
wash
correspond
antirabbit
dylight
conjug
secondari
antibodi
bethyl
laboratori
bethesda
md
ad
h
wash
filoviru
infectioninduc
focu
form
unit
ffu
measur
well
plate
perkin
elmer
waltham
use
cell
imag
multimod
reader
pair
softwar
biotek
winooski
vt
marvzsg
gfp
cell
count
directli
day
pi
without
need
fixat
antibodi
stain
object
len
use
take
overlap
imag
encompass
entir
well
assembl
analyz
ffu
rang
size
rel
fluoresc
signal
camera
gain
set
integr
time
msec
use
led
intens
set
averag
number
background
cell
count
subtract
well
give
normal
cell
count
neg
valu
adjust
analysi
experiment
replic
highest
number
posit
count
regard
count
use
posit
follow
normal
data
fit
variabl
slope
nonlinear
regress
fit
mean
valu
deriv
quadrupl
sampl
measur
compound
inhibit
infecti
filoviru
yield
cell
infect
tcid
sudv
ravv
per
cell
h
viru
inoculum
remov
cell
wash
phosphat
buffer
salin
replac
cultur
medium
contain
respect
compound
dilut
seri
day
pi
supernat
harvest
serial
dilut
mix
vero
cell
per
well
well
plate
day
pi
plate
fix
formalin
supplement
tritonx
deterg
stain
primari
rabbit
antiebov
serum
sever
wash
correspond
antirabbit
dylight
conjug
secondari
antibodi
ad
plate
visual
assay
use
microscop
fluoresc
cell
quantit
tissu
tcid
assay
use
reed
muench
method
reed
muench
ec
valu
calcul
use
fourparamet
variabl
slope
nonlinear
regress
fit
mean
valu
deriv
quadrupl
sampl
similarli
measur
compound
inhibit
infecti
henipaviru
yield
cell
infect
tcid
niv
hev
per
cell
h
viru
inoculum
remov
cell
wash
phosphat
buffer
salin
replac
cultur
medium
contain
compound
dilut
seri
h
pi
supernat
harvest
serial
dilut
mix
vero
cell
per
well
plate
day
pi
plate
visual
assay
cpe
viru
titer
quantit
tissu
tcid
assay
use
reed
muench
method
reed
muench
ec
valu
calcul
use
fourparamet
variabl
slope
nonlinear
regress
fit
mean
valu
deriv
quadrupl
sampl
confirm
antivir
mechan
action
analog
depict
fig
b
c
respect
first
perform
cellfre
vitro
rsv
polymeras
assay
rsv
polymeras
form
dimer
l
p
protein
rsv
lp
accept
rna
templat
primer
gener
short
rna
synthesi
product
fig
noton
et
al
rsv
lp
extend
primer
base
addit
p
gtp
fig
lane
fulli
extend
base
addit
atp
ctp
fig
lane
individu
substitut
cytidin
analog
place
natur
ctp
understand
potenti
effect
nonobligatori
chain
termin
rna
synthesi
assay
fig
lane
ctp
ctp
termin
rna
synthesi
rsv
lp
posit
recogn
almost
equal
enzym
consist
observ
cytidin
analog
inhibit
rsv
polymeras
similar
assay
intracellular
phosphoryl
level
c
c
highli
depend
cell
type
previou
studi
observ
differ
level
antivir
activ
henipavirus
depend
cell
line
use
consist
lower
antivir
activ
hela
cell
human
epitheli
lung
carcinoma
cell
line
investig
whether
differ
due
cellular
phosphoryl
level
measur
intracellular
phosphoryl
human
cell
line
hela
cervic
adenocarcinoma
line
hepatoma
line
sknmc
neuroepithelioma
line
cell
line
treat
h
intracellular
triphosph
level
measur
use
tandem
liquid
chromatographymass
spectrometri
lcmsm
quantit
use
synthet
standard
level
correspond
triphosph
measur
cell
line
highest
level
seen
cell
pmolmillion
cell
fig
phosphoryl
lowest
cell
sknmc
cell
pmolmillion
cell
respect
addit
contain
substitut
examin
effect
substitut
ntp
level
use
cell
line
highest
ntp
level
hela
cell
treat
c
c
h
ntp
format
measur
quantifi
previous
describ
fig
cell
line
c
level
highest
follow
c
higher
overal
ntp
level
nucleosid
seen
cell
light
result
decid
use
cell
cellbas
viral
infect
assay
c
c
show
minim
cytotox
cell
ensur
antivir
effect
observ
studi
due
cytotox
effect
attribut
compound
measur
viabil
cell
continu
incub
vari
dilut
compound
day
fig
compound
produc
low
cytotox
day
post
treatment
c
result
mild
cytotox
highest
concentr
use
day
treatment
fig
even
day
post
treatment
cell
cytotox
cc
level
reach
c
c
show
superior
antivir
activ
compar
recombin
report
niv
rsv
measl
viru
human
parainfluenza
viru
initi
evalu
antivir
activ
c
c
recombin
report
rsv
hallak
et
al
measl
viru
rmv
ez
egfp
rennick
et
al
human
parainfluenza
zhang
et
al
niv
lo
et
al
express
green
fluoresc
report
protein
fig
wherea
ec
valu
virus
consist
singledigit
micromolar
rang
c
c
inhibit
viru
potent
tabl
c
c
inhibit
rmv
ez
egfp
similar
concentr
tabl
c
measur
potent
c
fig
tabl
c
also
inhibit
moder
strongli
c
measur
gfp
report
assay
fig
cpe
inhibit
assay
data
shown
tabl
evalu
antivir
activ
c
c
wildtyp
niv
hev
measur
inhibit
henipavirusinduc
cpe
infecti
viru
yield
fig
similar
observ
c
c
inhibit
nivand
hevinduc
cpe
significantli
greater
potenc
c
margin
potent
c
fig
b
accordingli
c
c
reduc
infecti
henipaviru
yield
order
magnitud
fig
wherea
requir
similar
viru
yield
reduct
although
assay
ec
valu
c
c
ident
hev
within
niv
tabl
c
caus
sharper
declin
niv
hev
titer
c
fig
ebov
variant
suscept
inhibit
c
less
suscept
c
inhibit
recent
work
describ
broadspectrum
activ
adenosin
nucleotid
analog
across
paramyxovirida
pneumovirida
filovirida
famili
document
conserv
amino
acid
nucleotidebind
domain
polymeras
virus
may
explain
suscept
similar
compound
light
work
alongsid
studi
document
antivir
activ
c
c
hcv
rsv
klumpp
et
al
smith
et
al
smith
et
al
wang
et
al
test
antivir
activ
compound
recombin
report
mayinga
makona
ebov
variant
genu
ebolaviru
speci
zair
ebolaviru
express
green
fluoresc
protein
albarino
et
al
towner
et
al
fig
b
c
inhibit
ebov
variant
similarli
henipavirus
approxim
ec
valu
respect
tabl
contrast
observ
henipavirus
howev
c
time
less
potent
ebov
ec
valu
rang
tabl
compound
neglig
inhibit
report
rvfv
belong
famili
phenuivirida
outsid
order
mononegaviral
fig
confirm
observ
test
compound
wildtyp
ebov
makona
variant
measur
inhibit
ebov
infect
spread
use
imagebas
plate
reader
quantifi
ebov
infect
percentag
ebov
antigenposit
focusform
unit
ffu
detect
fig
observ
dosedepend
inhibit
ffu
format
c
treatment
detect
signific
inhibit
c
fig
tabl
test
compound
gulu
variant
sudv
genu
ebolaviru
speci
sudan
ebolaviru
phylogenet
diverg
rel
ebov
prior
respons
largest
filoviru
outbreak
human
lamunu
et
al
sanchez
rollin
c
inhibit
sudv
efficaci
similar
observ
ebov
ffu
assay
fig
ec
valu
c
accordingli
c
inhibit
sudv
less
potent
compound
ec
valu
approxim
tabl
evalu
antivir
activ
cytidin
analog
sudv
measur
infecti
viru
yield
fig
c
reduc
infecti
sudv
titer
order
magnitud
concentr
respect
respect
ec
valu
hand
c
reduc
infecti
viru
yield
approxim
order
magnitud
highest
concentr
use
assay
fig
determin
antivir
activ
compound
phylogenet
diverg
member
genu
ebolaviru
proceed
test
anoth
filoviru
ravn
viru
ravv
genu
marburgviru
speci
marburg
marburgviru
compar
ebov
sudv
determin
phylogenet
diverg
member
genu
marburgviru
nucleotid
diverg
towner
et
al
use
ffu
assay
observ
inhibit
ravv
lower
potenc
ebov
sudv
ec
valu
fig
tabl
c
c
howev
inhibit
ravv
similarli
ebov
sudv
ec
valu
respect
measur
infecti
ravv
product
presenc
compound
similar
observ
sudv
c
reduc
infecti
ravv
titer
order
magnitud
concentr
respect
respect
ec
valu
c
fig
tabl
c
reduc
ravv
titer
roughli
order
magnitud
highest
concentr
use
ec
valu
fig
tabl
verifi
antivir
activ
observ
cell
line
perform
report
cpe
assay
niv
use
human
primari
fig
c
c
reduc
henipaviru
cytopath
effect
cpe
infecti
viru
yield
repres
dose
respons
curv
green
circl
c
blue
triangl
c
red
squar
wildtyp
niv
b
hendra
viru
hev
measur
cpe
determin
cpe
assay
independ
repeat
least
time
compound
niv
hev
reduct
infecti
niv
c
hev
yield
c
c
tcid
ml
valu
log
scale
data
point
repres
mean
triplic
c
quadrupl
c
infect
experi
concentr
dilut
seri
compound
perform
dot
line
indic
limit
detect
error
bar
indic
standard
deviat
mean
valu
mk
lo
et
al
antivir
research
small
airway
epitheli
cell
saec
shown
support
robust
niv
replic
escaffr
et
al
report
cpe
assay
util
recombin
report
viru
observ
potent
inhibit
c
respect
ec
valu
fig
tabl
inhibit
gfp
cpe
could
visual
observ
treatment
c
complet
abolish
gfp
express
well
cpe
saec
fig
hand
observ
markedli
lower
antivir
activ
c
indic
respect
intracellular
ntp
level
like
lower
level
observ
cell
sinc
filoviruspseudotyp
lentivirus
effici
transduc
airway
epitheli
cell
vivo
kobing
et
al
proceed
evalu
antivir
activ
nucleosid
saec
report
marburg
viru
marvzsg
express
green
fluoresc
protein
cell
treat
serial
dilut
c
observ
dosedepend
inhibit
marv
infect
ffu
assay
wherea
c
show
signific
inhibit
fig
tabl
compar
higher
ec
valu
c
marvzsg
saec
observ
ravv
cell
like
due
lower
intracellular
ntp
level
studi
character
antivir
properti
analog
c
c
use
cellfre
cellbas
assay
despit
presenc
group
analog
compound
behav
like
convent
nonobligatori
rna
synthesi
chain
termin
cellfre
rsv
polymeras
assay
order
nucleosid
analog
retain
antivir
function
insid
cell
multipl
cellular
kinas
requir
convert
activ
triphosph
form
ray
hitchcock
better
understand
cell
typedepend
variabl
previous
observ
antivir
activ
measur
cellular
level
differ
cell
line
observ
higher
level
ctp
ctp
cell
hela
cell
compar
elev
ntp
level
observ
cell
may
attribut
higher
express
level
uridinecytidin
kinas
catalyz
presum
initi
ratelimit
step
phosphoryl
uridin
cytidin
nucleosid
van
rompay
et
al
character
cell
line
optim
line
use
studi
highlight
import
confirm
cellular
triphosph
level
conduct
antivir
screen
nucleosid
analog
librari
observ
significantli
decreas
antivir
activ
c
c
cell
report
ebov
data
shown
like
explain
overal
lower
phosphoryl
level
cytidin
analog
cell
line
fig
higher
potenc
c
c
paramyxovirus
howev
sole
attribut
ntp
level
sinc
level
higher
ctp
level
cell
fig
moreov
chang
rank
order
antifilovir
potenc
cellbas
assay
suggest
differ
antivir
activ
due
differenti
recognit
discrimin
ntp
analog
viral
polymeras
gelbas
biochem
assay
use
rsv
polymeras
provid
qualit
result
inform
mainli
mechan
action
compound
demonstr
substrat
recognit
chain
termin
fig
provid
enough
inform
rank
order
potenc
andor
discrimin
three
nucleotid
evalu
compound
primari
human
saec
confirm
potent
antiniv
activ
c
fig
antimarv
activ
c
fig
studi
includ
two
relat
nucleosid
klumpp
et
al
littl
antivir
activ
niv
ebov
respect
data
shown
result
warrant
studi
compar
antivir
potenc
ntp
analog
recombin
paramyxoviru
filoviru
polymeras
although
technic
challeng
preclud
work
fig
c
c
inhibit
sudan
viru
sudv
repres
doserespons
curv
green
circl
c
blue
triangl
c
red
squar
sudv
gulu
variant
use
focu
form
unit
ffu
assay
ffu
assay
c
perform
repeat
c
b
reduct
infecti
sudv
yield
log
scale
c
c
tcid
ml
valu
log
scale
data
point
repres
mean
quadrupl
infect
concentr
dilut
seri
compound
perform
fig
c
c
inhibit
marburgviru
ravn
viru
ravv
repres
doserespons
curv
green
circl
c
blue
triangl
c
red
squar
ravv
use
ffu
assay
ffu
assay
independ
repeat
four
time
twice
c
three
time
c
dose
respons
curv
fit
mean
valu
experi
perform
quadrupl
concentr
dilut
seri
use
nonlinear
logist
regress
curv
variabl
slope
b
reduct
infecti
ravv
yield
log
scale
c
c
tcid
ml
valu
data
point
repres
mean
quadrupl
infect
concentr
dilut
seri
compound
perform
recent
jordan
et
al
abil
cytidin
analog
reduc
henipaviru
filoviru
infecti
yield
log
tcid
ml
mirror
viral
inhibit
adenosin
analog
phosphoramid
nucleotid
prodrug
inhibit
filovirus
coronavirus
nonhuman
primat
mous
model
respect
current
phase
clinic
trial
treatment
ebov
diseas
evd
sheahan
et
al
warren
et
al
favipiravir
also
known
broadspectrum
small
molecul
nucleosid
precursor
origin
develop
treat
influenza
viru
also
decreas
ebov
infecti
yield
logtcid
ml
albeit
high
concentr
yetundefin
mechan
baranovich
et
al
oestereich
et
al
adenosin
nucleosid
analog
variabl
vitro
broadspectrum
activ
across
viru
famili
includ
filovirida
current
phase
clinic
trial
treat
evd
taylor
et
al
warren
et
al
although
inhibit
hcv
polymeras
similarli
convent
chain
termin
also
reduc
infecti
filoviru
yield
mechan
action
negativestrand
virus
unclear
neither
analog
viabl
candid
antivir
therapeut
due
variabl
incorpor
host
mitochondri
rna
dna
polymeras
arnold
et
al
clark
et
al
provid
initi
comparison
filo
fig
c
potent
inhibit
report
niv
gene
express
gfp
cytopath
effect
cpe
human
primari
small
airway
epitheli
cell
repres
dose
respons
curv
green
circl
c
blue
triangl
c
red
squar
recombin
report
niv
measur
gfp
express
h
postinfect
measur
b
cpe
inhibit
h
postinfect
data
point
error
bar
indic
mean
valu
standard
deviat
biolog
replic
c
bright
field
bf
fluoresc
gfp
microscopi
uninfect
control
dmso
treat
infect
control
c
treat
infect
saec
concentr
c
indic
white
bar
indic
distanc
paramyxoviru
suscept
nucleosid
studi
provid
evid
support
develop
nucleosid
nearequival
potenc
mononegaviral
order
famili
also
positivesens
flavivirida
famili
develop
smallmolecul
broadspectrum
therapeut
treat
phylogenet
diverg
viral
infect
share
signific
epidemiolog
clinic
overlap
eg
ebov
yellow
fever
viru
niv
japanes
enceph
viru
would
benefit
clinician
access
rapid
diagnost
amidst
outbreak
seriou
viral
infect
tabl
mean
antivir
activ
c
c
primari
human
small
airway
epitheli
cell
ec
effect
inhibit
concentr
si
select
index
ec
cc
rep
report
cpe
cytopath
effect
ffu
focusform
unit
nd
determin
rec
recombin
mean
valu
standard
deviat
valu
deriv
minimum
independ
experi
perform
biolog
quadrupl
